Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 147 No. 2122 (2017)

Leucopenia associated with metamizole: a case-control study

  • Lea S. Blaser
  • Hala Hassna
  • Sarah Hofmann
  • Andreas Holbro
  • Manuel Haschke
  • Alexandra E. Rätz Bravo
  • Andreas Zeller
  • Stephan Krähenbühl
  • Anne B. Taegtmeyer
DOI
https://doi.org/10.4414/smw.2017.14438
Cite this as:
Swiss Med Wkly. 2017;147:w14438
Published
24.05.2017

Summary

References

  1. Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J. 2007;21(10):2343–51. PubMed http://dx.doi.org/10.1096/fj.06-8061com https://doi.org/10.1096/fj.06-8061com
  2. Zugelassene Praeparate. Erweiterte Praeparatliste. Available from https://www.swissmedic.ch/arzneimittel/00156/00221/00222/00230/index.html?lang=de. Last accessed 14th February 2017
  3. Chan TY, Chan AW. Aminopyrine-induced blood dyscrasias--still a problem in many parts of the world. Pharmacoepidemiol Drug Saf. 1996;5(4):215–9. PubMed http://dx.doi.org/10.1002/(SICI)1099-1557(199607)5:4<215::AID-PDS208>3.0.CO;2-5 https://doi.org/10.1002/(SICI)1099-1557(199607)5:4<215::AID-PDS208>3.0.CO;2-5
  4. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002;58(4):265–74. PubMed http://dx.doi.org/10.1007/s00228-002-0465-2 https://doi.org/10.1007/s00228-002-0465-2
  5. Blaser LS, Tramonti A, Egger P, Haschke M, Krähenbühl S, Rätz Bravo AE. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol. 2015;71(2):209–17. PubMed http://dx.doi.org/10.1007/s00228-014-1781-z https://doi.org/10.1007/s00228-014-1781-z
  6. Huber M, Andersohn F, Sarganas G, Bronder E, Klimpel A, Thomae M, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol. 2015;71(2):219–27. PubMed http://dx.doi.org/10.1007/s00228-014-1777-8 https://doi.org/10.1007/s00228-014-1777-8
  7. Product Information Novalgin®, sanofi-aventis (schweiz) ag, 1214 Vernier/GE. Available from http://www.swissmedicinfo.ch. Last accessed 14th February 2017.
  8. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84(7):428–34. PubMed http://dx.doi.org/10.1002/ajh.21433 https://doi.org/10.1002/ajh.21433
  9. Anonymous. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA. 1986;256(13):1749–57. PubMed http://dx.doi.org/10.1001/jama.1986.03380130077032 https://doi.org/10.1001/jama.1986.03380130077032
  10. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657–65. PubMed http://dx.doi.org/10.7326/0003-4819-146-9-200705010-00009 https://doi.org/10.7326/0003-4819-146-9-200705010-00009
  11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. PubMed http://dx.doi.org/10.1038/clpt.1981.154 https://doi.org/10.1038/clpt.1981.154
  12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. PubMed http://dx.doi.org/10.7326/0003-4819-150-9-200905050-00006 https://doi.org/10.7326/0003-4819-150-9-200905050-00006
  13. Haahr M. List randomizer. Available from: https://www.random.org/. Last ascessed 08.10.2015.
  14. Adverse drug reaction and causality assessment scales. WHO. Available from: http://who-umc.org/Graphics/24734.pdf. Last accessed 22.02.2016.
  15. Zeiner E, Blaser LS, Tisljar K, Heim D, Taegtmeyer A. Fatale Agranulozytose nach Metamizol-Reexposition. Praxis (Bern). 2015;104(3):151–4. http://dx.doi.org/10.1024/1661-8157/a001916 https://doi.org/10.1024/1661-8157/a001916
  16. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–74. PubMed http://dx.doi.org/10.1001/archinte.165.8.869 https://doi.org/10.1001/archinte.165.8.869
  17. Théophile H, Bégaud B, Martin K, Laporte JR, Capella D. Incidence of agranulocytosis in Southwest France. Eur J Epidemiol. 2004;19(6):563–5. PubMed http://dx.doi.org/10.1023/B:EJEP.0000032371.97823.85 https://doi.org/10.1023/B:EJEP.0000032371.97823.85
  18. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol. 2005;60(11):821–9. PubMed http://dx.doi.org/10.1007/s00228-004-0836-y https://doi.org/10.1007/s00228-004-0836-y
  19. Navarro-Martínez R, Chover-Sierra E, Cauli O. Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital. Hum Exp Toxicol. 2016;35(3):244–50. PubMed http://dx.doi.org/10.1177/0960327115580603 https://doi.org/10.1177/0960327115580603
  20. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127(3, Suppl):S74–81. PubMed http://dx.doi.org/10.1016/j.jaci.2010.11.048 https://doi.org/10.1016/j.jaci.2010.11.048
  21. Vlahov V, Bacracheva N, Tontcheva D, Naumova E, Mavrudieva M, Ilieva P, et al. Genetic factors and risk of agranulocytosis from metamizol. Pharmacogenetics. 1996;6(1):67–72. PubMed http://dx.doi.org/10.1097/00008571-199602000-00005 https://doi.org/10.1097/00008571-199602000-00005
  22. Cheung CL, Sing CW, Tang CS, Cheng VK, Pirmohamed M, Choi CH, et al. HLA-B*38:02:01 Predicts Carbimazole/Methimazole-Induced Agranulocytosis. Clin Pharmacol Ther. 2015;99(5):555–61. doi:10.1002/cpt.309. PubMed
  23. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf. 1997;16(1):1–8. PubMed http://dx.doi.org/10.2165/00002018-199716010-00001 https://doi.org/10.2165/00002018-199716010-00001
  24. Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. Br J Dermatol. 2015;172(4):1090–5. PubMed http://dx.doi.org/10.1111/bjd.13512 https://doi.org/10.1111/bjd.13512
  25. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al.; Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr. 2000;23(3):236–45. PubMed http://dx.doi.org/10.1097/00126334-200003010-00004 https://doi.org/10.1097/00126334-200003010-00004
  26. Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, et al.; Antiprotease Cohort (APROCO) Study Group. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis. 2004;39(2):248–55. PubMed http://dx.doi.org/10.1086/422141 https://doi.org/10.1086/422141
  27. Guitton E, Montastruc JL, Lapeyre-Mestre M; French Network of Pharmacovigilance Centres. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol. 2006;62(3):243–9. PubMed http://dx.doi.org/10.1007/s00228-005-0080-0 https://doi.org/10.1007/s00228-005-0080-0
  28. Levy M, Leibowich I, Zylber-Katz E, Ilan Y, Granit L, Sviri S, et al. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus. Clin Pharmacol Ther. 1997;62(1):6–14. PubMed http://dx.doi.org/10.1016/S0009-9236(97)90145-4 https://doi.org/10.1016/S0009-9236(97)90145-4
  29. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. PubMed http://dx.doi.org/10.1002/hep.26141 https://doi.org/10.1002/hep.26141
  30. Kedia S, Bhatt VR, Rajan SK, Tandra PK, El Behery RA, Akhtari M. Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. Int J Prev Med. 2014;5(Suppl 3):S179–92. PubMed
  31. Abou El Azm AR, El-Bate H, Abo-Ali L, Mansour N, Ghoraba H, Salem ML. Correlation of viral load with bone marrow and hematological changes in pale patients with chronic hepatitis C virus. Arch Virol. 2012;157(8):1579–86. PubMed http://dx.doi.org/10.1007/s00705-012-1321-z https://doi.org/10.1007/s00705-012-1321-z
  32. Medrano-Casique N, Tong HY, Borobia AM, Carcas AJ, Frías J, Ramírez E. Non-Chemotherapy-Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital. Basic Clin Pharmacol Toxicol. 2015;117(6):399–408. PubMed http://dx.doi.org/10.1111/bcpt.12418 https://doi.org/10.1111/bcpt.12418

Most read articles by the same author(s)

1 2 > >>